Active bmn 111: daily subcutaneous injection of 15 ug/kg of bmn 111 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 276 | Achondroplasia | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03989947 (ClinicalTrials.gov) | June 12, 2019 | 22/5/2019 | An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia | A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia | Achondroplasia | Drug: Active BMN 111: Daily subcutaneous injection of 15 ug/kg of BMN 111 | BioMarin Pharmaceutical | NULL | Enrolling by invitation | 15 Months | N/A | All | 70 | Phase 2 | United States;Australia;Japan;United Kingdom |